CT and PET imaging in non-small cell lung cancer

Lung cancer is the leading cause of cancer mortality among both males and females throughout the world. Worldwide, as many as one million people are affected by the disease each year. Within the United States over 170,000 cases of lung cancer are diagnosed annually and over 150,000 lung cancer death...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2006-04, Vol.58 (1), p.15-30
Main Authors: Knoepp, Ursula W., Ravenel, James G.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - diagnosis
Computed tomography (CT)
Female
Fluorodeoxyglucose F18
Hematologic and hematopoietic diseases
Humans
Lung cancer
Lung Neoplasms - diagnosis
Male
Medical sciences
Neoplasm Metastasis - diagnosis
Neoplasm Staging
Pneumology
Positron emission tomography (PET)
Positron-Emission Tomography
Tomography, X-Ray Computed
Tumors of the respiratory system and mediastinum
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer mortality among both males and females throughout the world. Worldwide, as many as one million people are affected by the disease each year. Within the United States over 170,000 cases of lung cancer are diagnosed annually and over 150,000 lung cancer deaths will occur. Due to its prevalence, lung cancer has a great impact on health care costs annually, making it a significant public health issue. Appropriate therapy is dependent on accurate staging to determine those amenable to surgery and define the appropriate role for chemotherapy and radiation therapy. In this review, we discuss the impact of computed tomography (CT) and positron emission tomography (PET) with a primary focus on 18F-fluorodeoxyglucose (18F-FDG) on lung cancer evaluation and staging.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2005.09.001